Monopar Therapeutics’ (MNPR) Hold Rating Reiterated at Jones Trading

Jones Trading reiterated their hold rating on shares of Monopar Therapeutics (NASDAQ:MNPR) in a research note published on Wednesday, Marketbeat Ratings reports.

Other research analysts have also recently issued reports about the company. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Monopar Therapeutics in a research report on Tuesday. Piper Sandler reiterated an “overweight” rating and issued a $76.00 price objective on shares of Monopar Therapeutics in a research note on Wednesday, March 19th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $44.00.

Monopar Therapeutics Stock Down 13.3 %

Shares of MNPR opened at $30.00 on Wednesday. Monopar Therapeutics has a twelve month low of $1.72 and a twelve month high of $54.30. The company has a market capitalization of $183.39 million, a P/E ratio of -15.23 and a beta of 1.01. The firm has a 50 day moving average of $38.29 and a 200 day moving average of $24.88.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings data on Monday, March 31st. The company reported ($2.23) EPS for the quarter, missing the consensus estimate of ($0.36) by ($1.87). On average, sell-side analysts expect that Monopar Therapeutics will post -1.65 EPS for the current year.

Insiders Place Their Bets

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 33,334 shares of the business’s stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the sale, the insider now directly owns 822,255 shares of the company’s stock, valued at $28,778,925. The trade was a 3.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 34.90% of the company’s stock.

Institutional Investors Weigh In On Monopar Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MNPR. Janus Henderson Group PLC purchased a new stake in Monopar Therapeutics in the fourth quarter worth about $23,435,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of Monopar Therapeutics in the 4th quarter valued at about $13,182,000. RA Capital Management L.P. purchased a new stake in shares of Monopar Therapeutics in the 4th quarter worth approximately $11,247,000. Point72 Asset Management L.P. bought a new position in shares of Monopar Therapeutics during the fourth quarter valued at approximately $3,694,000. Finally, ADAR1 Capital Management LLC purchased a new position in Monopar Therapeutics during the fourth quarter valued at approximately $2,861,000. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.